Latest filing published 18 May 2022 for Recursion Pharmaceuticals, INC., €4,519.
Insider track record
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Ramona Doyle: trading record in brief
This profile gathers the share dealings of Ramona Doyle in Recursion Pharmaceuticals, Inc., where the filings describe the role as senior executive. In total, 8 filings cover trades dated from 3 January 2022 to 16 May 2022.
Not one of the filings records a straightforward purchase or sale on the market. Because grants and exercises are largely decided by remuneration plans, they are not counted as purchases here.
Most recently, on 18 May 2022, the filings show a share grant worth €4,519 in Recursion Pharmaceuticals, Inc. The median gap between a trade and its publication by SEC (Form 4) is 3 days. Section 16 rules allow two business days to file each Form 4. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Companies and markets linked to Ramona Doyle
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 832 shares@ US$5.672.5% of flowClass A Common StockSEC:0001209191-22-030255:0
- 9,072 shares@ US$2.4811.2% of flowClass A Common StockSEC:0001209191-22-022310:0
- 15,625 shares@ US$2.4819.1% of flowClass A Common StockSEC:0001209191-22-014405:0
- 38,499 shares0Class A Common StockSEC:0001209191-22-007915:0
- 15,625 shares@ US$2.4819.1% of flowClass A Common StockSEC:0001209191-22-006598:0
- 40,322 shares@ US$2.4748.2% of flowClass A Common StockSEC:0001209191-22-002062:0
6 of 6 declarations
